SEC Comment Letter 0000000000-23-014198 to HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma Inc.
Date: Dec. 29, 2023 · CIK: 0001760542 · Accession: 0000000000-23-014198
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276220
Letter
United States securities and exchange commission logo December 29, 2023 Joern Aldag Chief Executive Officer HOOKIPA Pharma Inc. 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, NY 10118 Re:HOOKIPA Pharma Inc. Registration Statement on Form S-3 Filed December 22, 2023 File No. 333-276220 Dear Joern Aldag: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Finn Murphy, Esq.
Show Raw Text
United States securities and exchange commission logo
December 29, 2023
Joern Aldag
Chief Executive Officer
HOOKIPA Pharma Inc.
350 Fifth Avenue, 72nd Floor, Suite 7240
New York, NY 10118
Re:HOOKIPA Pharma Inc.
Registration Statement on Form S-3
Filed December 22, 2023
File No. 333-276220
Dear Joern Aldag:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Finn Murphy, Esq.